Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPO-166
- Development stage
- Unknown
- Lead developer
- Conjupro Biotherapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CPO-166 is an orally bioavailable small molecule inhibitor of cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6) currently under development by CONJ Biotherapeutics. By simultaneously targeting CDK2 along with CDK4 and CDK6, CPO-166 is designed to overcome the resistance mechanisms that frequently emerge during treatment with selective CDK4/6 inhibitors in patients with metastatic breast cancer. The inhibition of these kinases prevents the phosphorylation of the retinoblastoma (Rb) protein, leading to cell-cycle arrest in the G1 phase and the suppression of tumor cell proliferation. The drug is currently being evaluated in Phase 2 clinical trials for the treatment of metastatic breast cancer.
Beyond the preview
Go deeper on CPO-166.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPO-166.